Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females

123Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: A long-acting FSH preparation has been developed by site-directed mutagenesis and gene transfer techniques. Methods: In this open-label trial, we investigated the pharmacokinetic and pharmacodynamic properties of FSH-CTP (corifollitropin alpha, Org 36286) in healthy female volunteers. Twenty-four subjects were treated with a high-dose oral contraceptive (OC) to suppress pituitary function. A single dose of 15, 30 or 60 μg FSH-CTP was injected (s.c., eight subjects per dose group) and seven of these 24 subjects were subsequently treated with a single dose of 120 μg. Results: Maximum serum FSH-CTP concentrations (0.42, 0.66, 1.49 and 3.27 ng/ml after administration of 15, 30, 60 and 120 μg Org 36286 respectively) were reached between 36 and 48 h after injection and t1/2 varied between 60 and 75 h. Dose proportionality was shown across the studied dose range, whereas tmax and t1/2 were dose independent. In most subjects follicular growth was observed; the number and maximum diameter of the follicles increased with the dose. Follicles with a diameter ≥8.0 mm were observed only in the 60 and 120 μg dose groups, diameters between 12.0 and 15.9 mm occured only in the 120 μg group. Serum LH and 17β-oestradiol levels remained low due to profound pituitary suppression whereas inhibin-B levels increased with dose. Maximum mean inhibin-B levels were 30.4, 322.7 and 1059.3 pg/ml in the 30, 60 and 120 μg dose group respectively. The preparation was safe and well tolerated, and no FSH-CTP antibody formation was observed. Conclusions: The pharmacokinetics of FSH-CTP were shown to be proportional with the dose. The elimination half-life was approximately two times longer than that of rFSH. A single dose of FSH-CTP was shown to be safe and able to induce multiple follicular growth accompanied by a dose-dependent rise in serum inhibin-B concentrations.

Cite

CITATION STYLE

APA

Duijkers, I. J. M., Klipping, C., Boerrigter, P. J., Machielsen, C. S. M., De Bie, J. J., & Voortman, G. (2002). Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Human Reproduction, 17(8), 1987–1993. https://doi.org/10.1093/humrep/17.8.1987

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free